Efficacy of citalopram on stroke recurrence: A randomized clinical trial

Basit Öğe Kaydı
dc.authorscopusid57710502200
dc.authorscopusid7003717249
dc.authorscopusid15768235000
dc.authorscopusid57710502300
dc.authorscopusid6701401491
dc.contributor.authorCetin, Fatma Ece
dc.contributor.authorKumral, Emre
dc.contributor.authorGonul, Ali Saffet
dc.contributor.authorOzdemir, Hueseyin Nezih
dc.contributor.authorOrman, Mehmet
dc.date.accessioned2023-01-12T19:55:24Z
dc.date.available2023-01-12T19:55:24Z
dc.date.issued2022
dc.departmentN/A/Departmenten_US
dc.description.abstractPost-stroke depression is one of the main causes of cerebrovascular and cardiovascular diseases. The aim of the present study was to investigate the efficacy of citalopram on stroke recurrence. A 52-week, randomized, double-blind, study involved 440 ischemic stroke patients with depression. Patients with depression who met depression criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV and V) and Hamilton Depression Rating Scale >= 8 (HAM-DRS) were dichotomized into patients receiving citalopram (225 patients), titrated according to clinical response, and patients with placebo (215 patients) for 52 weeks. The primary outcome measure was stroke recurrence and the secondary outcome measures were cardiovascular events and mortality. Stroke recurrence (66% vs 34%; P = 0.001) and cardiovascular events (76% vs. 24%; P = o.oo1) were significantly higher in the placebo group compared to those treated with citalopram. Multivariable analysis showed that hypertension, atrial fibrillation, and large-artery disease were significantly associated with stroke recurrence. Executive processing disorder was more associated with stroke recurrence than other neuropsychological disorders (OR, 1.74; CI95%, 1.04-2.89; P = 0.035). Survival analysis showed that treatment for depression interacted with time to reduce stroke recurrence by nearly half (39% vs. 61%; P = 0.05). The current study supports the importance of depression treatment in protecting the patients from recurrent strokes. This result warrants further studies to demonstrate the efficacy of depression treatment on stroke recurrence.en_US
dc.identifier.doi10.1016/j.jocn.2022.05.014
dc.identifier.endpage174en_US
dc.identifier.issn0967-5868
dc.identifier.issn1532-2653
dc.identifier.pmid35597066en_US
dc.identifier.scopus2-s2.0-85130716648en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage168en_US
dc.identifier.urihttps://doi.org/10.1016/j.jocn.2022.05.014
dc.identifier.urihttps://hdl.handle.net/11454/76675
dc.identifier.volume101en_US
dc.identifier.wosWOS:000804723900017en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Sci Ltden_US
dc.relation.ispartofJournal of Clinical Neuroscienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMood disorderen_US
dc.subjectCitalopramen_US
dc.subjectOutcomeen_US
dc.subjectStroke recurrenceen_US
dc.subjectCoronary-Heart-Diseaseen_US
dc.subjectPoststroke Depressionen_US
dc.subjectCognitive Impairmenten_US
dc.subjectRisken_US
dc.subjectSymptomsen_US
dc.subjectMetaanalysisen_US
dc.subjectMortalityen_US
dc.subjectDementiaen_US
dc.subjectOutcomesen_US
dc.titleEfficacy of citalopram on stroke recurrence: A randomized clinical trialen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu